Alyeska Investment Group, L.P. Tricida, Inc. Transaction History

Alyeska Investment Group, L.P.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$3.95 - $5.41 $149,013 - $204,092	-37,725 Reduced 33.47%	75,000 $324,000
Q1 2021 May 17, 2021	SELL	$4.52 - $7.8 $512,852 - $885,011	-113,463 Reduced 50.16%	112,725 $596,000
Q3 2020 Nov 16, 2020	BUY	$8.56 - $26.93 $225,128 - $708,259	26,300 Added 13.16%	226,188 $2.05 Million
Q2 2020 Aug 14, 2020	BUY	$21.21 - $31.55 $1.15 Million - $1.71 Million	54,100 Added 37.11%	199,888 $5.49 Million
Q1 2020 May 15, 2020	BUY	$18.43 - $38.04 $701,427 - $1.45 Million	38,059 Added 35.33%	145,788 $3.21 Million
Q4 2019 Feb 14, 2020	BUY	$29.6 - $43.71 $186,065 - $274,761	6,286 Added 6.2%	107,729 $4.07 Million
Q3 2019 Nov 14, 2019	BUY	$29.87 - $42.22 $811,508 - $1.15 Million	27,168 Added 36.58%	101,443 $3.13 Million
Q2 2019 Aug 14, 2019	BUY	$31.16 - $39.46 $1.54 Million - $1.95 Million	49,399 Added 198.58%	74,275 $0
Q1 2019 May 15, 2019	SELL	$19.96 - $38.62 $2,475 - $4,788	-124 Reduced 0.5%	24,876 $0
Q2 2018 Aug 14, 2018	BUY	$26.0 - $29.9 $650,000 - $747,500	25,000 New	25,000 $748,000

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Alyeska Investment Group, L.P., based on Form 13F filings with the SEC.

Stay updated on Alyeska Investment Group, L.P. with notifications on news.